| 1. |
Wang F, Qin S, Lou F, et al. Retrospective analysis of immune checkpoint inhibitor-associated myocarditis from12 cancer centers in China. J Clin Oncol, 2020, 38(15 Suppl): e15130.
|
| 2. |
Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol, 2021, 16: 223-249.
|
| 3. |
Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol, 2022, 40(6): 586-597.
|
| 4. |
Ulas EB, Dickhoff C, Schneiders FL, et al. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. ESMO Open, 2021, 6(5): 100244.
|
| 5. |
Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov, 2022, 21(7): 495-508.
|
| 6. |
魏娟, 趙利軍, 祝宇, 等. 替雷利珠單抗致重度免疫相關性肝炎 1 例. 中國藥師, 2022, 25(7): 1217-1219.
|
| 7. |
de Filette J, Andreescu CE, Cools F, et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res, 2019, 51(3): 145-156.
|
| 8. |
Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol, 2017, 13(4): 195-207.
|
| 9. |
Jaafar J, Fernandez E, Alwan H, et al. Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocr Connect, 2018, 7(5): R196-R211.
|
| 10. |
Yamauchi I, Sakane Y, Fukuda Y, et al. Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid, 2017, 27(7): 894-901.
|
| 11. |
Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med, 2021, 9(3): 305-314.
|
| 12. |
Tan MH, Iyengar R, Mizokami-Stout K, et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol, 2019, 5: 1.
|
| 13. |
Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol, 2021, 17(7): 389-399.
|
| 14. |
Lakomy R, Poprach A, Kazda T. Management of immune-related endocrinopathies in anticancer treatment with checkpoint inhibitors. Klin Onkol, 2020, 33(1): 15-19.
|
| 15. |
Duan L, Wang L, Wang H, et al. Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. Thorac Cancer, 2020, 11(4): 1099-1104.
|
| 16. |
Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw, 2019, 17(3): 255-289.
|
| 17. |
Mosaferi T, Tsai K, Sovich S, et al. Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from hashimoto’s thyroiditis. Thyroid, 2022, 32(5): 496-504.
|
